dQM QICore Content Implementation Guide
2025.0.0 - CI Build
dQM QICore Content Implementation Guide, published by cqframework. This guide is not an authorized publication; it is the continuous build for version 2025.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/cqframework/dqm-content-qicore-2025/ and changes regularly. See the Directory of published versions
Official URL: https://madie.cms.gov/Measure/CMS819FHIRHHORAE | Version: 1.0.000 | |||
Active as of 2025-08-25 | Responsible: Centers for Medicare & Medicaid Services (CMS) | Computable Name: CMS819FHIRHHORAE | ||
Other Identifiers: Short Name: CMS819FHIR (use: usual, ), UUID:30256069-ee4f-45b8-895a-5452cf8e9e4e (use: official, ), UUID:d58ce964-1cb1-40b5-a4aa-40b030191990 (use: official, ), Endorser: 3501e (use: official, ), Publisher: 819FHIR (use: official, ) | ||||
Copyright/Legal: Limited proprietary coding is contained in the Measure specifications for user convenience. Users of proprietary code sets should obtain all necessary licenses from the owners of the code sets. Mathematica disclaims all liability for use or accuracy of any third-party codes contained in the specifications. LOINC(R) copyright 2004-2024 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2024 International Health Terminology Standards Development Organisation. ICD-10 copyright 2024 World Health Organization. All Rights Reserved. |
This measure assesses the number of inpatient hospitalizations for patients age 18 and older who have been administered an opioid medication and are subsequently administered an opioid antagonist within 12 hours, an indication of an opioid-related adverse event
Metadata | |
---|---|
Title | Hospital Harm - Opioid-Related Adverse EventsFHIR |
Version | 1.0.000 |
Short Name | CMS819FHIR |
GUID (Version Independent) | urn:uuid:30256069-ee4f-45b8-895a-5452cf8e9e4e |
GUID (Version Specific) | urn:uuid:d58ce964-1cb1-40b5-a4aa-40b030191990 |
CMS Identifier | 819FHIR |
CMS Consensus Based Entity Identifier | 3501e |
Effective Period | 2026-01-01 through 2026-12-31 |
Steward (Publisher) | Centers for Medicare & Medicaid Services (CMS) |
Developer | Mathematica |
Description | This measure assesses the number of inpatient hospitalizations for patients age 18 and older who have been administered an opioid medication and are subsequently administered an opioid antagonist within 12 hours, an indication of an opioid-related adverse event |
Copyright | Limited proprietary coding is contained in the Measure specifications for user convenience. Users of proprietary code sets should obtain all necessary licenses from the owners of the code sets. Mathematica disclaims all liability for use or accuracy of any third-party codes contained in the specifications. LOINC(R) copyright 2004-2024 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2024 International Health Terminology Standards Development Organisation. ICD-10 copyright 2024 World Health Organization. All Rights Reserved. |
Disclaimer | This performance measure is not a clinical guideline, does not establish a standard of medical care and has not been tested for all potential applications. THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND. Due to technical limitations, registered trademarks are indicated by (R) or [R] and unregistered trademarks are indicated by (TM) or [TM]. |
Rationale | Opioids are often the foundation for sedation and pain relief. Opioid-based analgesia continues to be the most commonly used treatment in postoperative pain management, with more than 95% of surgical patients receiving opioids during their hospitalization (Baker et al., 2020). However, use of opioids can also lead to serious adverse events, including constipation, over sedation, delirium, and respiratory depression (Urman et al., 2021a). Opioid-related adverse events (ORADE) have both patient-level and financial implications. The presence of an ORADE was associated with a 55% longer postoperative length of stay, 29% lower odds of discharge home, and 2.9 times the odds of death (Urman et al., 2021b). For surgical patients, occurrence of opioid-related adverse events was associated with an increase of 1.6 days in length of stay (LOS) and $8225 more in cost for the index hospitalization. Patients who experienced ORADEs while in a hospitalized setting were more likely to have received a higher total dose of opioids during hospitalization (Cone et al., 2023; Shafi et al., 2018). Numerous studies report the additive (risk-adjusted) hospitalization cost burden of surgical patients with ORADEs to be between $4350-$8225, representing a 27-47% increase in (risk-adjusted) admission costs (Khanna et al., 2021). Most opioid-related adverse events are preventable. Each year, adverse drug events (ADE) account for nearly 700,000 emergency department visits and 100,000 hospitalizations (AHRQ, 2019). An estimated one-third of all adverse events that occur in the inpatient setting are adverse drug events (ODPHP, 2020). Additionally, in a closed-claims analysis, 97% of adverse events were judged preventable with better monitoring and response (Lee et al., 2015). Naloxone administration is often used as an indicator of a severe opioid-related adverse event, and implementation of this measure can advance safe use of opioids in hospitals and prevent these serious and potentially lethal adverse drug events. |
Clinical Recommendation Statement | Naloxone is an opioid reversal agent typically used for severe opioid-related adverse events. Naloxone administration has been used in a number of studies as an indicator of opioid-related adverse events (Yiu, et al., 2022; Lynn & Galinkin, 2017; Nwulu et al., 2013). From Section 10 of the 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care (Lavonas et al., 2015), the following recommendation is listed for use of naloxone: Naloxone is a potent opioid receptor antagonist in the brain, spinal cord, and gastrointestinal system. Naloxone has an excellent safety profile and can rapidly reverse central nervous system (CNS) and respiratory depression in a patient with an opioid-associated resuscitative emergency. The 2020 American Heart Association guidelines update for cardiopulmonary resuscitation continue to recommend naloxone for a patient with suspected opioid overdose who has a definite pulse but no normal breathing or only gasping (i.e., a respiratory arrest), in addition to providing standard Pediatric Basic Life Support (PBLS) or Pediatric Advanced Life Support (PALS), it is reasonable for responders to administer intramuscular or intranasal naloxone. These recommendations are identical for adults (American Heart Association, 2020). In February 2022, the Food and Drug Administration (FDA) approved its abbreviated new drug application for nalmefene hydrochloride injection, 2mg/2mL (1mg/1mL). Nalmefene is an opioid antagonist indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids, and in the management of known or suspected opioid overdose (FDA, 2022). In contrast to naloxone, the long half-life of nalmefene is similar to or greater than that of many opioid receptor agonists (Britch & Walsh, 2022), which could decrease the need for repeat drug administration. In May 2023, FDA approved nalmefene hydrochloride nasal spray that delivers 2.7 milligrams (mg) of nalmefene into the nasal cavity (FDA, 2023). |
Citation | Agency for Healthcare Research and Quality. (2019). Medication Errors and Adverse Drug Events. Rockville: US Department of Health & Human Services. Retrieved from https://psnet.ahrq.gov/primer/medication-errors-and-adverse-drug-events |
Citation | American Heart Association and American Society of Anesthesiologists. (2021). Naloxone in CPR/AED Training and Public Access to Defibrillation. Retrieved from https://www.heart.org/-/media/Files/About-Us/Policy-Research/Policy-Positions/CPR-and-AED/Naloxone-Position-Statement.pdf |
Citation | American Heart Association. (2020). Highlights of the 2020 American Heart Association's Guidelines for CPR and ECC. https://cpr.heart.org/-/media/cpr-files/cpr-guidelines-files/highlights/hghlghts_2020_ecc_guidelines_english.pdf |
Citation | Baker, J., Brovman, E.Y., Rao, N., Beutler, S.S., Urman, R.D. (2020). Potential Opioid-Related Adverse Drug Events Are Associated With Decreased Revenue in Hip Replacement Surgery in the Older Population. Geriatric Orthopaedic Surgery & Rehabilitation. January 2020. doi:10.1177/2151459320915328 |
Citation | Britch, S.C., Walsh, S.L. (2022). Treatment of opioid overdose: current approaches and recent advances. Psychopharmacology (Berl). 2022;239(7):2063-2081. doi:10.1007/s00213-022-06125-5 |
Citation | Food and Drug Administration. (2022). Nalmefene Hydrochloride Injection 2mg/2mL (1mg/1mL) [Full Prescribing Information]. Stamford, CT: Purdue Pharma L.P., 02/08/2022. https://www.accessdata.fda.gov/spl/data/d4bb0797-a4ed-4ed4-9904-604433eea4ff/d4bb0797-a4ed-4ed4-9904-604433eea4ff.xml |
Citation | Kessler, E. R., Shah, M., Gruschkus, S. K., & Raju, A. (2013). Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: opioid-related adverse events and their impact on clinical and economic outcomes. Pharmacotherapy, 33(4), 383-391. doi: 10.1002/phar.1223 |
Citation | Khanna, A.K., Saager, L., Bergese, S.D., et al. (2021). Opioid-induced respiratory depression increases hospital costs and length of stay in patients recovering on the general care floor. BMC Anesthesiol. 2021;21(1):88. Published 2021 Mar 20. doi:10.1186/s12871-021-01307-8 |
Citation | Lavonas, E. J., Drennan, I. R., Gabrielli, A., Heffner, A. C., Hoyte, C. O., Orkin, A. M., Donnino, M. W. (2015). Part 10: Special Circumstances of Resuscitation. 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care, 132(18 suppl 2), S501-S518. doi: 10.1161/cir.0000000000000264 |
Citation | Lee, L. A., Caplan, R. A., Stephens, L. S., Posner, K. L., Terman, G. W., Voepel-Lewis, T., & Domino, K. B. (2015). Postoperative opioid-induced respiratory depression: a closed claims analysis. Anesthesiology, 122(3), 659-665 |
Citation | Lynn, R. R., Galinkin, J. (2017). Naloxone dosage for opioid reversal: Current evidence and clinical implications. Therapeutic Advances in Drug Safety, 9(1), 63-88. doi:10.1177/204209861774416 |
Citation | Makary, M. A., Daniel, M. (2016). Medical error-the third leading cause of death in the US. BMJ, 353, i2139. doi: 10.1136/bmj.i2139 |
Citation | Med Lett Drugs Ther. (2022). Nalmefene Returns for Reversal of Opioid Overdose. Sep 5;64(1658):141-2 |
Citation | Nwulu, U., Nirantharakumar, K., Odesanya, R., McDowell, S. E., Coleman, J. J. (2013). Improvement in the detection of adverse drug events by the use of electronic health and prescription records: an evaluation of two trigger tools. Eur J Clin Pharmacol, 69(2), 255-259. doi: 10.1007/s00228-012-1327-1 |
Citation | Shafi, S., Collinsworth, A.W., Copeland, L.A., et al. (2018). Association of Opioid-Related Adverse Drug Events With Clinical and Cost Outcomes Among Surgical Patients in a Large Integrated Health Care Delivery System. JAMA Surg. 2018;153(8):757-763. doi:10.1001/jamasurg.2018.1039. PMID: 29799927; PMCID: PMC6142954 |
Citation | Urman, R.D., Khanna, A.K., Bergese, S.D., et al. (2021). Postoperative opioid administration characteristics associated with opioid-induced respiratory depression: Results from the PRODIGY trial. J Clin Anesth. 2021;70:110167. doi:10.1016/j.jclinane.110167 |
Citation | Urman, R.D., Seger, D.L., Fiskio, J.M., et al. (2021). The Burden of Opioid-Related Adverse Drug Events on Hospitalized Previously Opioid-Free Surgical Patients. J Patient Saf. 2021;17(2):e76-e83 |
Guidance (Usage) | Qualifying encounters (denominator) include all patients 18 years of age or older with at least one opioid medication administered outside of the operating room. To create the numerator: 1. First, start with those encounters meeting denominator criteria. 2. Next, remove all events where an opioid or opioid antagonist was administered in the operating room. Opioid antagonist administrations in the operating room are excluded because they could be part of the sedation plan as administered by an anesthesiologist. Encounters that include use of opioid antagonists for procedures and recovery outside of the operating room (e.g., bone marrow biopsy and PACU) are included in the numerator, as it would indicate the patient was over-sedated. Note that should a facility not utilize temporary patient locations, alternative times may be used to determine whether a patient is in the operating room during opioid antagonist administration. Since anesthesia end time could represent the time the anesthesiologist signed off, and thus may include the patient's time in the PACU, this should be avoided. 3. Next, remove all events where the opioid antagonist was administered via an enteral route. Only opioid antagonists given by a non-enteral (i.e., intravenous, intramuscular, subcutaneous, intranasal, inhalation) route are considered. 4. Finally, remove all administrations of opioid antagonist that were given greater than 12 hours following hospital administration of an opioid medication. This dQM is an episode-based measure. An episode is defined as each inpatient hospitalization or encounter that ends during the measurement period. This FHIR-based measure has been derived from the QDM-based measure: CMS819v4. Please refer to the HL7 QI-Core Implementation Guide (https://hl7.org/fhir/us/qicore/STU6/) for more information on QI-Core and mapping recommendations from QDM to QI-Core STU 6 (https://hl7.org/fhir/us/qicore/STU6/qdm-to-qicore.html). |
Measure Group (Rate) (ID: Group_1) | |
Basis | Encounter |
Scoring | [http://terminology.hl7.org/CodeSystem/measure-scoring#proportion: 'Proportion'] |
Type | [http://terminology.hl7.org/CodeSystem/measure-type#outcome: 'Outcome'] |
Rate Aggregation | None |
Improvement Notation | [http://terminology.hl7.org/CodeSystem/measure-improvement-notation#decrease: 'Decreased score indicates improvement'] |
Initial Population |
ID: InitialPopulation_1
Description: Inpatient hospitalizations that end during the measurement period for patients age 18 and older and at least one opioid medication administration starts during the hospitalization outside of the operating room Logic Definition: Initial Population |
Denominator |
ID: Denominator_1
Description: Equals Initial Population Logic Definition: Denominator |
Numerator |
ID: Numerator_1
Description: Inpatient hospitalizations where a non-enteral opioid antagonist administration starts during the hospitalization outside of the operating room and 12 hours or less following an opioid medication administered outside of the operating room. The route of administration of the opioid antagonist must be by intranasal spray, inhalation, intramuscular, subcutaneous, or intravenous injection. Only one numerator event is counted per encounter. Logic Definition: Numerator |
Supplemental Data Guidance | For every patient evaluated by this measure also identify payer, race, ethnicity and sex |
Supplemental Data Elements | |
Supplemental Data Element |
ID: sde-ethnicity
Usage Code: [http://terminology.hl7.org/CodeSystem/measure-data-usage#supplemental-data] Description: SDE Ethnicity Logic Definition: SDE Ethnicity |
Supplemental Data Element |
ID: sde-payer
Usage Code: [http://terminology.hl7.org/CodeSystem/measure-data-usage#supplemental-data] Description: SDE Payer Logic Definition: SDE Payer |
Supplemental Data Element |
ID: sde-race
Usage Code: [http://terminology.hl7.org/CodeSystem/measure-data-usage#supplemental-data] Description: SDE Race Logic Definition: SDE Race |
Supplemental Data Element |
ID: sde-sex
Usage Code: [http://terminology.hl7.org/CodeSystem/measure-data-usage#supplemental-data] Description: SDE Sex Logic Definition: SDE Sex |
Measure Logic | |
Primary Library | https://madie.cms.gov/Library/CMS819FHIRHHORAE |
Contents |
Population Criteria
Logic Definitions Terminology Dependencies Data Requirements |
Population Criteria | |
Measure Group (Rate) (ID: Group_1) | |
Initial Population | |
|
|
Denominator | |
|
|
Numerator | |
|
|
Logic Definitions | |
Logic Definition | Library Name: SupplementalDataElements |
|
|
Logic Definition | Library Name: SupplementalDataElements |
|
|
Logic Definition | Library Name: SupplementalDataElements |
|
|
Logic Definition | Library Name: SupplementalDataElements |
|
|
Logic Definition | Library Name: CMS819FHIRHHORAE |
|
|
Logic Definition | Library Name: CMS819FHIRHHORAE |
|
|
Logic Definition | Library Name: CMS819FHIRHHORAE |
|
|
Logic Definition | Library Name: CMS819FHIRHHORAE |
|
|
Logic Definition | Library Name: CMS819FHIRHHORAE |
|
|
Logic Definition | Library Name: CMS819FHIRHHORAE |
|
|
Logic Definition | Library Name: CMS819FHIRHHORAE |
|
|
Logic Definition | Library Name: CMS819FHIRHHORAE |
|
|
Logic Definition | Library Name: CMS819FHIRHHORAE |
|
|
Logic Definition | Library Name: CMS819FHIRHHORAE |
|
|
Logic Definition | Library Name: CMS819FHIRHHORAE |
|
|
Logic Definition | Library Name: CMS819FHIRHHORAE |
|
|
Logic Definition | Library Name: CQMCommon |
|
|
Logic Definition | Library Name: CQMCommon |
|
|
Logic Definition | Library Name: QICoreCommon |
|
|
Logic Definition | Library Name: FHIRHelpers |
|
|
Logic Definition | Library Name: FHIRHelpers |
|
|
Logic Definition | Library Name: FHIRHelpers |
|
|
Logic Definition | Library Name: FHIRHelpers |
|
|
Terminology | |
Code System |
Description: Code system SNOMEDCT
Resource: http://snomed.info/sct Canonical URL: http://snomed.info/sct |
Value Set |
Description: Value set Opioid Antagonist
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.119 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.119 |
Value Set |
Description: Value set Opioids, All
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.226 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.226 |
Value Set |
Description: Value set Encounter Inpatient
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.307 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.307 |
Value Set |
Description: Value set Observation Services
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.143 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.143 |
Value Set |
Description: Value set Emergency Department Visit
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.292 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.292 |
Value Set |
Description: Value set Operating Room Suite
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.141 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.141 |
Value Set |
Description: Value set Routes of Administration for Opioid Antagonists
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.187 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.187 |
Value Set |
Description: Value set Payer Type
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3591 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3591 |
Direct Reference Code |
Display: Male (finding)
Code: 248153007 System: http://snomed.info/sct |
Direct Reference Code |
Display: Female (finding)
Code: 248152002 System: http://snomed.info/sct |
Dependencies | |
Dependency |
Description: QICore model information
Resource: http://hl7.org/fhir/Library/QICore-ModelInfo Canonical URL: http://hl7.org/fhir/Library/QICore-ModelInfo |
Dependency |
Description: Library SDE
Resource: https://madie.cms.gov/Library/SupplementalDataElements|5.1.000 Canonical URL: https://madie.cms.gov/Library/SupplementalDataElements|5.1.000 |
Dependency |
Description: Library FHIRHelpers
Resource: https://madie.cms.gov/Library/FHIRHelpers|4.4.000 Canonical URL: https://madie.cms.gov/Library/FHIRHelpers|4.4.000 |
Dependency |
Description: Library QICoreCommon
Resource: https://madie.cms.gov/Library/QICoreCommon|4.0.000 Canonical URL: https://madie.cms.gov/Library/QICoreCommon|4.0.000 |
Dependency |
Description: Library CQMCommon
Resource: https://madie.cms.gov/Library/CQMCommon|4.1.000 Canonical URL: https://madie.cms.gov/Library/CQMCommon|4.1.000 |
Data Requirements | |
Data Requirement |
Type: Patient
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-patient Must Support Elements: extension, url |
Data Requirement |
Type: MedicationAdministration
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-medicationadministration Must Support Elements: medication, status, status.value, effective, dosage, dosage.route Code Filter(s): Path: medication ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.119 |
Data Requirement |
Type: MedicationAdministration
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-medicationadministration Must Support Elements: medication, status, status.value, effective, dosage, dosage.route Code Filter(s): Path: medication ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.226 |
Data Requirement |
Type: MedicationAdministration
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-medicationadministration Must Support Elements: medication.reference.value, status, status.value, effective, dosage, dosage.route |
Data Requirement |
Type: Medication
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-medication Must Support Elements: id.value, code |
Data Requirement |
Type: Encounter
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-encounter Must Support Elements: type, status, status.value, period, location Code Filter(s): Path: type ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.143 |
Data Requirement |
Type: Encounter
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-encounter Must Support Elements: type, status, status.value, period, location Code Filter(s): Path: type ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.292 |
Data Requirement |
Type: Encounter
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-encounter Must Support Elements: type, period, status, status.value, location Code Filter(s): Path: type ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.307 |
Data Requirement |
Type: Resource
Profile(s): http://hl7.org/fhir/StructureDefinition/Resource Must Support Elements: id, id.value |
Data Requirement |
Type: Location
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-location |
Data Requirement |
Type: Coverage
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-coverage Must Support Elements: type, period Code Filter(s): Path: type ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3591 |
Generated using version 0.4.8 of the sample-content-ig Liquid templates |